Pharma-Bio Serv posts $7.3M sales, $252K profit
PBSV increased revenue and turned a year-to-date profit, while posting only a small net loss in its fiscal third quarter.
Rhea-AI Filing Summary
Pharma-Bio Serv, Inc. (PBSV) reported higher revenue and improved profitability for the quarter and nine months ended July 31, 2026. Revenue was approximately $2.3 million for the quarter and $7.3 million for the nine-month period, up about $0.4 million and $0.5 million, respectively, from the same periods a year earlier.
For the quarter, the company recorded a small net loss of $14 thousand, while for the nine months it generated net income of approximately $252 thousand, representing improvements of about $190 thousand and $352 thousand versus the prior-year periods. Chief Executive Officer Victor Sanchez stated that the results reflect strong client relationships, the company’s specialized regulatory and compliance capabilities, and ongoing efforts to focus on markets where its expertise provides a competitive advantage and to drive operating efficiencies.
Positive
- Revenue grew to $2.3 million for the quarter and $7.3 million year-to-date, with absolute increases of $0.4 million and $0.5 million versus last year.
- Profitability improved, with a nine-month net income of $252 thousand, a positive swing of about $352 thousand compared with the prior-year period.
Negative
- None.
Key Figures
Quarterly revenue: $2.3 million
Nine-month revenue: $7.3 million
Quarterly revenue increase: $0.4 million
+5 more
8 metrics
Quarterly revenue
$2.3 million
For the three months ended July 31, 2026
Nine-month revenue
$7.3 million
For the nine months ended July 31, 2026
Quarterly revenue increase
$0.4 million
Increase versus the same quarter of the prior year
Nine-month revenue increase
$0.5 million
Increase versus the same nine-month period of the prior year
Quarterly net loss
$14 thousand
Net loss for the three months ended July 31, 2026
Nine-month net income
$252 thousand
Net income for the nine months ended July 31, 2026
Quarterly net result improvement
$190 thousand
Improvement in net result versus the same quarter of the prior year
Nine-month net result improvement
$352 thousand
Improvement in net result versus the prior-year nine-month period
Key Terms
forward-looking statements, regulatory compliance consulting, Annual Report on Form 10-K, Risk Factors
4 terms
forward-looking statements regulatory
"This news release contains “forward-looking statements” within the meaning of the U.S. federal"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
regulatory compliance consulting regulatory
"Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting"
Annual Report on Form 10-K regulatory
"those set forth in the “Risk Factors” section of Pharma-Bio Serv's Annual Report on Form 10-K"
An annual report on Form 10‑K is a required, comprehensive filing that publicly traded companies give to regulators and investors summarizing their business, results of operations, detailed financial statements reviewed by independent auditors, material risks, legal issues and management’s discussion of performance. Investors use it like a company’s year‑end report card and medical checkup: it reveals how the business made money, where it is vulnerable, and the facts needed to compare value, judge risk and make informed investment decisions.
Risk Factors regulatory
"Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the “Risk Factors” section"
Risk factors are elements or conditions that could cause an investment's value to decrease or lead to potential losses. They are like warning signs or obstacles that can affect the success of an investment, making it uncertain or more unpredictable. Recognizing risk factors helps investors understand the possible challenges and make more informed decisions.
Earnings Snapshot
Revenue (quarter): $2.3 million
Quarter and nine months ended July 31, 2026
Revenue (quarter)
$2.3 million
$0.4 million increase vs. prior-year quarter
Revenue (nine months)
$7.3 million
$0.5 million increase vs. prior-year period
Net loss (quarter)
$14 thousand
$190 thousand improvement vs. prior-year quarter
Net income (nine months)
$252 thousand
$352 thousand improvement vs. prior-year period
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How did PBSV’s revenue perform for the quarter ended July 31, 2026?
PBSV reported quarterly revenue of approximately $2.3 million for the three months ended July 31, 2026, an increase of about $0.4 million compared with the same quarter in the prior year.
What were PBSV’s year-to-date revenues for the nine months ended July 31, 2026?
For the nine months ended July 31, 2026, PBSV generated revenue of approximately $7.3 million, an increase of about $0.5 million over the corresponding period of the prior year.
Did PBSV report a profit or loss in the third quarter of 2026?
For the quarter ended July 31, 2026, PBSV reported a small net loss of $14 thousand, which was an improvement of about $190 thousand compared with the same quarter a year earlier.
What was PBSV’s net income for the nine months ended July 31, 2026?
PBSV reported net income of approximately $252 thousand for the nine months ended July 31, 2026, representing an improvement of about $352 thousand compared with the prior-year period.
What strategic focus did PBSV highlight in the July 31, 2026 results?
PBSV highlighted a focus on markets where its specialized regulatory and compliance expertise provides a competitive advantage and on driving operating efficiencies, which management stated contributed to the improved financial performance.
AI-generated analysis. How Rhea-AI works. Not financial advice.
